SUPPLEMENTARY FIGURES



Supplementary Figure 1. The flow chart summarizing the process for the identification of the eligible clinical studies.

		Hazard Ratio	Hazard Ratio
Study or Subgroup	1	IV, Fixed, 95% CI	IV, Fixed, 95% CI
Albanel 2021		0.48 [0.37, 0.62]	-
Goetz 2021,75		0.62 [0.34, 1.11]	
Goetz 2021 Ful		0.63 [0.45, 0.88]	
Goetz 2021 NSAI		0.61 [0.47, 0.79]	-
Goetz 2021 NSAI, 75		0.54 [0.26, 1.13]	
Rudo 2018, Let		0.66 [0.45, 0.97]	
Rudo 2018 Ful		0.27 [0.16, 0.46]	_
Rudo 2018 Ful75		0.59 [0.19, 1.83]	
Rugo 2018 Let75		0.31 [0.16, 0.60]	
Slamon 2018		0.59 [0.43, 0.81]	
Snoke 2018		0.60 [0.39, 0.92]	
Xu 2022		1.24 [0.58, 2.65]	
Zhang 2020 Ful		0.56 [0.24, 1.31]	
Zhang 2020 NSAI		2.50 [0.56, 11.16]	
Total (95% CI)	100.0%	0.56 [0.50, 0.63]	♦
Heterogeneity: Chi ² = 21.83, df = 13 (P = 0.06); l ² = 40%			
Test for overall effect: Z = 9.80 (P < 0.00001)			0.02 0.1 1 10 50 Favours [experimental] Favours [control]

Supplementary Figure 2. PFS in pairwise analysis.



Supplementary Figure 3. Inconsistency vs. consistency plot for Progression free survival of COK 4–6 treatments. Plot of individual data points for the consistency model (horizonal axis) and the inconsistency model (vertical axis), along with the equality line.